
OptimizeRx Corp (OPRX) Stock Forecast & Price Target
OptimizeRx Corp (OPRX) Analyst Ratings
Bulls say
OptimizeRx is positioned for significant growth as the transition from in-person to digital pharma/provider interactions creates new opportunities for revenue expansion in the high teens to low twenties, while also benefitting from improved margins. The company's current headcount is capable of supporting a revenue run-rate of approximately $150 million, indicating substantial operating leverage for the next 2-3 years. Notably, OptimizeRx demonstrated strong financial performance with a record AEBITDA of $12 million, nearly doubling prior estimates and reflecting the effectiveness of its cost management strategies amidst fluctuating revenue.
Bears say
OptimizeRx Corp has reduced its 2026 revenue guidance from $118M-$124M to $109M-$114M, indicating significant near-term challenges, with expectations of negative revenue growth between 10% to 12.5% year-over-year for the first half of the year due to weakened pharma spending amid pricing initiatives. The company's net revenue retention (NRR) has also declined, reflecting reduced investment from large pharma clients, and visibility into future revenue has decreased by 15-20% compared to the previous year. Despite strong gross margins and cost control, the unexpected revenue deceleration and uncertain economic conditions lead to a negative outlook for the stock.
This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.
OptimizeRx Corp (OPRX) Analyst Forecast & Price Prediction
Start investing in OptimizeRx Corp (OPRX)
Order type
Buy in
Order amount
Est. shares
0 shares